Andrew Joseph , 2025-05-13 16:45:00
LONDON — In announcing his plan to lower prescription drug prices, President Trump argued that both Americans and drug companies could benefit. Critical to making this happen, he said, would be getting Europeans — whom he cast as freeloaders in the global pharmaceutical system — to pay more for their medicines.
It may not be so easy.
In outlining his “most-favored nation” proposal to tie U.S. drug prices to those paid by other developed countries, Trump highlighted discrepancies between costs stateside versus those in Europe, a long-running fact that Trump framed as an injustice. No longer, he and other administration officials said, would the U.S. subsidize drugmakers’ research projects that resulted in medicines that benefited the whole world.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
